ArticleFrontiers in endocrinology2026
Association of metabolic dysfunction-associated steatotic liver disease trajectories with incident liver cancer: a UK Biobank cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a contributor to hepatocellular carcinoma. Whether repeated assessment of MASLD provides additional prognostic information for liver cancer risk remains unclear. Methods: Using the UK Biobank, we included 12,111 participants who underwent both baseline and follow-up health screenings. MASLD was defined at each assessment as fatty liver index ≥60 plus at least one cardiometabolic risk criterion. Four trajectory groups were defined: no MASLD → no MASLD, no MASLD → MASLD, MASLD → no MASLD, and MASLD → MASLD. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI). Results: At baseline, 4,008 participants (33.1%) had MASLD. MASLD at period 1 was associated with a higher risk of incident liver cancer compared with no MASLD (aHR, 2.81; 95% CI, 1.20-6.58). A similar association was observed for MASLD at period 2 (aHR, 2.61; 95% CI, 1.12-6.06). In trajectory analyses, MASLD → no MASLD (aHR, 4.00; 95% CI, 1.01-15.80) and MASLD → MASLD (aHR, 3.51; 95% CI, 1.31-9.44) were associated with higher liver cancer risk than no MASLD → no MASLD. Conclusions: MASLD at either assessment was associated with higher incident liver cancer risk. Trajectory analyses suggest that persistent MASLD and prior MASLD exposure may both carry prognostic importance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.